Hester Biosciences Limited
2,048.00
INR
-102.35
(-4.76%)
ISIN
INE782E01017
Return %
Stock
S&P 500
1Y
19.57
14.39
3Y
22.41
81.42
5Y
-16.98
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Rajiv Dinesh Gandhi
- Full Time Employees
- 483
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Pushpak, 1st Floor, Panchvati Circle, Motilal Hirabhai Road Ahmedabad GU India 380006
- IPO Date
- Aug 17, 1994
- Website
- hester.in
- Similar Companies
- Business
- Hester Biosciences Limited manufactures and markets animal health products, primarily vaccines and healthcare solutions for poultry and livestock, operating as one of India's leading animal healthcare companies and the second-largest poultry vaccine producer in the country with approximately 30-35% domestic market share. Founded in 1987 by Rajiv Gandhi and headquartered in Ahmedabad, Gujarat, the company offers a comprehensive portfolio spanning poultry vaccines (over 45 live and inactivated types including Newcastle Disease, Gumboro, and Marek's Disease), large animal vaccines (including goat pox with over 70% Indian market share, PPR from Nigerian and Sungri strains with global leadership at 75%, and others like Contagious Bovine Pleuropneumonia), poultry health products (pharmaceuticals, feed supplements, disinfectants, and herbal alternatives shifting away from antibiotics), animal health products, petcare offerings (anti-infectives, specialty nutrition, parasiticides, grooming launched in 2022), and services such as seroprofiling kits, diagnostic labs for poultry flocks, and mastitis control programs for cattle; it maintains Asia's largest single-location animal biological manufacturing facility in Gujarat, supplemented by plants in Nepal and Tanzania, an in-house R&D unit at Kadi with WHO-GMP and DSIR certifications, and a strategic presence across over 30 countries focused on India, Nepal, Tanzania, Africa, Vietnam, Indonesia, Bangladesh, and recently Egypt. Wholly-owned subsidiaries include Hester Biosciences Africa Limited in Tanzania (commissioned 2021 with USD 3 million investment), Hester Biosciences Kenya Limited (2018), and a 50% stake in Tanzania-based Thrishool Exim Limited acquired in 2022; past partnerships encompass Bill & Melinda Gates Foundation, GALVmed (including the world's largest backyard poultry immunization program), Golchha Organisation, and Novapharma for Egypt market entry. Recent developments feature capacity enhancement projects with additional bulk antigen infrastructure and state-of-the-art fill-finish lines for animal vaccines, Q1 FY26 consolidated net profit surge of 131% to Rs 17.3 crore driven by Hester Africa's turnaround and 2% revenue growth to Rs 84.11 crore, expansion of feed supplements and disinfectants gaining market traction in FY25, production commencement of Newcastle Disease, Gumboro, PPR, and CBPP vaccines, upcoming Avian Influenza vaccine launch and H9N2 approval with licensing expected by December 2025, strengthened sales/marketing/R&D reforms, petcare division product launches, and structural operational efficiencies supporting international scaling particularly in Africa.